A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673) Administered to Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer

Trial Profile

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673) Administered to Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms ABRAZO
  • Sponsors BioMarin Pharmaceutical; Medivation; Pfizer
  • Most Recent Events

    • 09 Dec 2017 Results of exposure-efficay and exposure-safety analysis presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 09 Dec 2017 Results assessing health-related quality of life presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top